VRTX insider transaction filings
VERTEX PHARMACEUTICALS INC / MA — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-10. Screen VRTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings by 4 insiders — 4,465 shares, $2,291,078 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 1,541 shares @ $519.00 ($799,779) by McKechnie Duncan, filed 2026-07-07.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| McKechnie Duncan — EVP, Chief Commercial Officer | 1 | — | 1 leg · 1,541 sh · $799,779 | — |
| Tatsis Ourania — EVP, Chief Reg. & Quality Off. | 2 | — | 1 leg · 1,500 sh · $787,485 | 1 |
| Liu Joy — EVP and Chief Legal Officer | 1 | — | 1 leg · 828 sh · $416,244 | — |
| Bozic Carmen — EVP and CMO | 1 | — | 1 leg · 596 sh · $287,570 | — |
| SACHS BRUCE I — Director | 2 | — | — | 2 |
| Ambrose Kristen — SVP & Chief Accounting Officer | 1 | — | — | 1 |
| Garber Alan M — Director | 1 | — | — | 1 |
| Sachdev Amit — EVP Chief Patient & Ext Af Off | 1 | — | — | 1 |
| van Grunsven Jasper — EVP, CP and NPPO | 1 | — | — | 1 |
Recent Form 4 filings — VERTEX PHARMACEUTICALS INC / MA
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | van Grunsven Jasper — EVP, CP and NPPO | Grant/award (A): 8,682 @ $0 | EDGAR |
| 2026-09-01 | 4 | Ambrose Kristen — SVP & Chief Accounting Officer | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2026-08-31 | 4 | SACHS BRUCE I — Director | Gift (G): 6,000 @ $0 | EDGAR |
| 2026-07-23 | 4 | Tatsis Ourania — EVP, Chief Reg. & Quality Off. | Grant/award (A): 8,251 @ $0 | EDGAR |
| 2026-07-23 | 4 | Sachdev Amit — EVP Chief Patient & Ext Af Off | Grant/award (A): 8,251 @ $0 | EDGAR |
| 2026-07-17 | 4 | Garber Alan M — Director | Grant/award (A): 31.56 (derivative) @ $475.28 | EDGAR |
| 2026-07-17 | 4 | SACHS BRUCE I — Director | Grant/award (A): 99.94 (derivative) @ $475.28 | EDGAR |
| 2026-07-07 | 4 | McKechnie Duncan — EVP, Chief Commercial Officer | Sale (S): 1,541 @ $519 | EDGAR |
| 2026-07-07 | 4 | Tatsis Ourania — EVP, Chief Reg. & Quality Off. | Sale (S): 1,500 @ $524.99 | EDGAR |
| 2026-07-06 | 4 | Liu Joy — EVP and Chief Legal Officer | Sale (S): 828 @ $502.71 | EDGAR |
| 2026-06-30 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 596 @ $482.50 | EDGAR |
| 2026-06-23 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 1,020 @ $462.17 | EDGAR |
| 2026-06-17 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 4,062 @ $450 | EDGAR |
| 2026-06-09 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 1,745 @ $450 | EDGAR |
| 2026-06-03 | 4 | Liu Joy — EVP and Chief Legal Officer | Sale (S): 828 @ $439.91 | EDGAR |
| 2026-06-02 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 1,974 @ $450 | EDGAR |
| 2026-05-19 | 4 | Bunnage Mark E. — EVP, Chief Scientific Officer | Sale (S): 33 @ $453.45 | EDGAR |
| 2026-05-19 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 1,354 @ $453.45 | EDGAR |
| 2026-05-14 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 6,988 @ $450 | EDGAR |
| 2026-05-05 | 4 | Liu Joy — EVP and Chief Legal Officer | Sale (S): 1,104 @ $425.02 | EDGAR |
| 2026-05-05 | 4 | Thornberry Nancy — Director | Grant/award (A): 472 @ $0 · Disposition to issuer (D): 398 · Grant/award (A): 1,433 (derivative) @ $0 · Grant/award (A): 398 (derivative) | EDGAR |
| 2026-05-05 | 4 | Schneider Jennifer — Director | Grant/award (A): 472 @ $0 · Disposition to issuer (D): 796 · Grant/award (A): 1,433 (derivative) @ $0 · Grant/award (A): 796 (derivative) | EDGAR |
| 2026-05-05 | 4 | MCKENZIE DIANA — Director | Grant/award (A): 943 @ $0 · Disposition to issuer (D): 796 · Grant/award (A): 796 (derivative) | EDGAR |
| 2026-05-05 | 4 | Bhatia Sangeeta N. — Director | Grant/award (A): 943 @ $0 · Sale (S): 318 @ $423.73 | EDGAR |
| 2026-05-05 | 4 | Upadhyay Suketu — Director | Disposition to issuer (D): 796 · Grant/award (A): 2,866 (derivative) @ $0 · Grant/award (A): 796 (derivative) | EDGAR |
| 2026-05-05 | 4 | Lagarde Michel — Director | Grant/award (A): 2,866 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Garber Alan M — Director | Grant/award (A): 472 @ $0 · Grant/award (A): 1,433 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | CARNEY LLOYD — Director | Grant/award (A): 2,866 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | SACHS BRUCE I — Director | Grant/award (A): 2,866 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Upadhyay Suketu — Director | Grant/award (A): 80.51 (derivative) @ $442.50 | EDGAR |
| 2026-04-17 | 4 | Garber Alan M — Director | Grant/award (A): 33.90 (derivative) @ $442.50 | EDGAR |
| 2026-04-17 | 4 | SACHS BRUCE I — Director | Grant/award (A): 107.34 (derivative) @ $442.50 | EDGAR |
| 2026-04-03 | 4 | Liu Joy — EVP and Chief Legal Officer | Sale (S): 978 @ $449.17 | EDGAR |
| 2026-03-31 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 2,329 @ $450.95 | EDGAR |
| 2026-03-17 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 2,329 @ $481.79 | EDGAR |
| 2026-03-13 | 4 | McKechnie Duncan — EVP, Chief Commercial Officer | Sale (S): 2,633 @ $498.42 | EDGAR |
| 2026-03-06 | 4 | McKechnie Duncan — EVP, Chief Commercial Officer | Sale (S): 2,437 @ $475.30 | EDGAR |
| 2026-03-04 | 4 | Liu Joy — EVP and Chief Legal Officer | Sale (S): 892 @ $495.96 | EDGAR |
| 2026-03-03 | 4 | Bozic Carmen — EVP and CMO | Sale (S): 2,329 @ $480.31 | EDGAR |
| 2026-03-03 | 4 | Kewalramani Reshma — CEO & President, Director | Sale (S): 400 @ $479.75 · Sale (S): 120 @ $481.50 · Sale (S): 240 @ $482.84 · Sale (S): 2,510 @ $487.13 · Sale (S): 3,278 @ $488.27 · Sale (S): 460 @ $489.32 · +7 more | EDGAR |
| 2026-03-02 | 4 | Ambrose Kristen — SVP & Chief Accounting Officer | Sale (S): 357 @ $483.36 | EDGAR |
| 2026-02-26 | 4 | Atkinson Edward Morrow III — EVP, Chief Technical Ops. Off. | Tax withholding (F): 1,627 @ $485.11 · Sale (S): 668 @ $486.35 | EDGAR |
| 2026-02-26 | 4 | Ambrose Kristen — SVP & Chief Accounting Officer | Tax withholding (F): 546 @ $485.11 · Sale (S): 223 @ $486.35 | EDGAR |
| 2026-02-26 | 4 | Bozic Carmen — EVP and CMO | Tax withholding (F): 1,453 @ $485.11 | EDGAR |
| 2026-02-26 | 4 | Tatsis Ourania — EVP, Chief Reg. & Quality Off. | Tax withholding (F): 1,627 @ $485.11 · Sale (S): 260 @ $486.35 | EDGAR |
| 2026-02-26 | 4 | Biller Jonathan — EVP and Chief Legal Officer | Tax withholding (F): 1,144 @ $485.11 · Sale (S): 945 @ $486.35 | EDGAR |
| 2026-02-26 | 4 | Kewalramani Reshma — CEO & President, Director | Tax withholding (F): 4,981 @ $485.11 | EDGAR |
| 2026-02-26 | 4 | Sachdev Amit — EVP Chief Patient & Ext Af Off | Tax withholding (F): 1,518 @ $485.11 · Sale (S): 1,846 @ $486.35 | EDGAR |
| 2026-02-26 | 4 | LEIDEN JEFFREY M — Executive Chairman, Director | Tax withholding (F): 3,547 @ $485.11 | EDGAR |
| 2026-02-26 | 4 | WAGNER CHARLES F JR — EVP, CO & FO | Tax withholding (F): 1,744 @ $485.11 | EDGAR |
Recent 8-K events — VERTEX PHARMACEUTICALS INC / MA
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →